-
On January 14, 2013, that the U.S. FDA approved a device allowing detection of multiple gastrointestinal pathogens from a single sample of feces.
-
A surgeon reported having suffered a sharps injury while performing an orthopedic procedure. Baseline testing found no evidence of HBV infection in the source patient, but determined that the surgeon had preexisting HBV infection, with positive HBsAg, positive HBeAg, negative IgM anti-HBc, and normal serum hepatic transaminases.
-
An analysis was performed of incident cases of tuberculosis in the United States reported to the Centers for Disease Control and Prevention from 2008-2010.
-
In the United States, approximately 50% of individuals develop antibodies to Epstein-Barr virus (EBV) by age 5.
-
-
A large outbreak of community acquired pneumonia due to macrolide-resistant M. pneumoniae (MRMP) occurred in Japan in 2011 and mainly affected school-age children.
-
In this issue: Apixaban approval; new dental clinical practice guideline; apixaban for VTE; aspirin resistance; tamoxifen treatment; and FDA actions.
-
-
Dolutegravir, a once daily hiv-1 integrase strand transfer inhibitor (INSTI), has been approved by the FDA.
-
Fluoroquinolones are commonly prescribed bactericidal agents with a wide spectrum of activity. In addition to the coverage against conventional gram-negative organisms, newer agents in this class have an expanded spectrum of activity against a variety of gram-positive and atypical organisms.